DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2cww39/triple_analysis) has announced the addition of the "Triple Analysis: Apoptosis, Cancer Vaccines and Protein Kinase Inhibitors" report to their offering.
This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology.
Key Topics Covered:
Part I: Apoptosis
5.1 The Scope of this Report
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy
9 Selecting Indication for Apoptotic Drugs in Oncology
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator
Part II: Cancer Vaccines
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs
8 Is First-in-Class the Best-in-Class?
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs
11 Selecting Indications for Cancer Vaccine Drugs
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company
Part III: Protein Kinase Inhibitors
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy
9 Selecting Indication for Protein Kinase Drugs in Oncology
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator
For more information visit http://www.researchandmarkets.com/research/2cww39/triple_analysis
